Efferon wants to eradicate the devastating toll of pediatric sepsis
- ID
- 34197
- Status
- summarized
- Published
- 11 Oct 2026, 11:00 PM
- Fetched
- 12 Oct 2026, 10:28 PM
- Provider
- TechCrunch
- Category
- technology
- Original URL
- https://techcrunch.com/2026/10/11/efferon-wants-to-eradicate-the-devastating-toll-of-pediatric-sepsis/
- Source URL
- https://techcrunch.com/feed/
Summary
- Score
- 2.0
- Created
- 12 Oct 2026, 10:29 PM
- Tags
- Audience
- startup_founders
What happened
Efferon, a TechCrunch Disrupt 2026 Startup Battlefield 200 pick, makes blood-purification absorbers that its co-founder and CEO Dima Romashin says remove both endotoxins and cytokines at once; its pediatric device, Efferon NEO, received a CE mark in April and is described as the first multimodal blood purification device engineered specifically for pediatric sepsis. The article says it is used in ICUs across 30 countries including European hospitals, Saudi Arabia and Thailand, that the company is preparing an FDA filing, and that it is on track for $2 million in annualized revenue by the end of the year. Pediatric sepsis is cited as claiming roughly 3 million children under five annually.
Why it matters
Almost nothing here is actionable for a software builder: the clinical efficacy claims, the 30-country footprint and the $2 million revenue run-rate are all company-stated in a startup profile, with no pricing, integration, API or policy detail a developer or SaaS founder can act on. The one transferable pattern is regulatory sequencing — Efferon NEO took a CE mark first and is only now filing for FDA — which is worth a sentence for founders planning hardware or health-adjacent launches, but it changes no decision for Malaysian software teams.
Discussion angle
Is CE-mark-first then FDA a realistic regulatory template for Southeast Asian hardware founders, and does a Thailand ICU deployment tell us anything about how foreign medtech gets into SEA hospitals?